Journal of Molecular Neuroscience

, Volume 41, Issue 1, pp 183–192 | Cite as

Nerve Growth Factor-Induced Protection of Brain Capillary Endothelial Cells Exposed to Oxygen–Glucose Deprivation Involves Attenuation of Erk Phosphorylation

  • Shimon Lecht
  • Hadar Arien-Zakay
  • Cezary Marcinkiewicz
  • Peter I. Lelkes
  • Philip LazaroviciEmail author


Nerve growth factor (NGF) was recently characterized as an angiogenic factor inducing proliferation, migration, and capillary sprouting in endothelial cells (ECs) of different vascular beds. While NGF neuroprotective effects on neurons were described, its survival-inducing effects on brain capillary ECs were not yet addressed. Using a model of oxygen–glucose deprivation (OGD) followed by reoxygenation, we demonstrated that NGF conferred protection in brain capillary ECs. These cells express TrkA and p75NTR receptors and respond to NGF by stimulation of Erk1/2 phosphorylation and stimulation of proliferation and migration. The NGF protective effect was dose-dependent, inhibited by NGF/TrkA antagonist, K252a, and required presence of NGF during both OGD and reoxygenation phases while the major protective effect was related to decreased cell death during the reoxygenation phase. A causal relationship was found between NGF-induced protection and attenuation of OGD-induced Erk1/2 phosphorylation, supporting the death-promoting role of insult-induced Erk1/2 phosphorylation in the brain capillary ECs. These results emphasize the importance of NGF in the process of EC survival in response to ischemic injury and suggest fine-tuning regulation of Erk1/2 phosphorylation, extending the neuroprotective impact of NGF from sympathetic neuroendocrine cells to brain capillary ECs as the other element in the neurovascular tandem.


Nerve growth factor Erk1/2 Oxygen–glucose deprivation and reoxygenation Protection Endothelial cells 



This research was supported in part by a grant-in-aid form the Stein Family Foundations (PL and PIL). PL is affiliated and partially supported by the David R. Bloom Center for Pharmacy and the Dr. Adolf and Klara Brettler Center for Research in Molecular Pharmacology and Therapeutics at The Hebrew University of Jerusalem, Israel. SL is supported by "Eshkol fellowship" from the Israeli Ministry of Science, Culture and Sport. The authors would like to acknowledge the help of Mr. Yoav Wagenstein for technical assistance and Mrs. Zehava Cohen for graphics design.


  1. Abu-Raya S, Trembovler V, Shohami E, Lazarovici P (1993) A tissue culture ischemic device to study eicosanoid release by pheochromocytoma PC12 cultures. J Neurosci Method 50:197–203CrossRefGoogle Scholar
  2. Abu-Raya S, Blaugrund E, Trembovler V, Shilderman-Bloch E, Shohami E, Lazarovici P (1999) Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-differentiated PC12 cells against oxygen–glucose deprivation. J Neurosci Res 58:456–463CrossRefPubMedGoogle Scholar
  3. Alessandrini A, Namura S, Moskowitz MA, Bonventre JV (1999) MEK1 protein kinase inhibition protects against damage resulting from focal cerebral ischemia. Proc Natl Acad Sci U S A 96:12866–12869CrossRefPubMedGoogle Scholar
  4. Andjelkovic AV, Stamatovic SM, Keep RF (2003) The protective effects of preconditioning on cerebral endothelial cells in vitro. J Cereb Blood Flow Metab 23:1348–1355CrossRefPubMedGoogle Scholar
  5. Arany I, Megyesi JK, Kaneto H, Price PM, Safirstein RL (2004) Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells. Am J Physiol Ren Physiol 287:F543–F549CrossRefGoogle Scholar
  6. Arien-Zakay H, Lecht S, Bercu MM, Tabakman R, Kohen R, Galski H et al (2009) Neuroprotection by cord blood neural progenitors involves antioxidants, neurotrophic and angiogenic factors. Exp Neurol 216:83–94CrossRefPubMedGoogle Scholar
  7. Bordet R, Lestage P, Onteniente B (2007) Neuroprotection: present and future. Therapie 62:473–476PubMedCrossRefGoogle Scholar
  8. Brown RC, Morris AP, O'Neil RG (2007) Tight junction protein expression and barrier properties of immortalized mouse brain microvessel endothelial cells. Brain Res 1130:17–30CrossRefPubMedGoogle Scholar
  9. Calvani M, Rapisarda A, Uranchimeg B, Shoemaker RH, Melillo G (2006) Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells. Blood 107:2705–2712CrossRefPubMedGoogle Scholar
  10. Cantarella G, Lempereur L, Presta M, Ribatti D, Lombardo G, Lazarovici P et al (2002) Nerve growth factor–endothelial cell interaction leads to angiogenesis in vitro and in vivo. FASEB J 16:1307–1309PubMedGoogle Scholar
  11. Chow J, Ogunshola O, Fan SY, Li Y, Ment LR, Madri JA (2001) Astrocyte-derived VEGF mediates survival and tube stabilization of hypoxic brain microvascular endothelial cells in vitro. Brain Res Dev Brain Res 130:123–132CrossRefPubMedGoogle Scholar
  12. Cristofaro B, Emanueli C (2009) Possible novel targets for therapeutic angiogenesis. Curr Opin Pharmacol 9:102–108CrossRefPubMedGoogle Scholar
  13. di Mari JF, Davis R, Safirstein RL (1999) MAPK activation determines renal epithelial cell survival during oxidative injury. Am J Physiol 277:F195–F203PubMedGoogle Scholar
  14. Dolle JP, Rezvan A, Allen FD, Lazarovici P, Lelkes PI (2005) Nerve growth factor-induced migration of endothelial cells. J Pharmacol Exp Ther 315:1220–1227CrossRefPubMedGoogle Scholar
  15. Eccles SA, Box C, Court W (2005) Cell migration/invasion assays and their application in cancer drug discovery. Biotechnol Annu Rev 11:391–421CrossRefPubMedGoogle Scholar
  16. Emanueli C, Salis MB, Pinna A, Graiani G, Manni L, Madeddu P (2002) Nerve growth factor promotes angiogenesis and arteriogenesis in ischemic hindlimbs. Circulation 106:2257–2262CrossRefPubMedGoogle Scholar
  17. Graiani G, Emanueli C, Desortes E, Van Linthout S, Pinna A, Figueroa CD et al (2004) Nerve growth factor promotes reparative angiogenesis and inhibits endothelial apoptosis in cutaneous wounds of type 1 diabetic mice. Diabetologia 47:1047–1054CrossRefPubMedGoogle Scholar
  18. Kallmann BA, Wagner S, Hummel V, Buttmann M, Bayas A, Tonn JC et al (2002) Characteristic gene expression profile of primary human cerebral endothelial cells. FASEB J 16:589–591PubMedGoogle Scholar
  19. Kaplan DR, Miller FD (2000) Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol 10:381–391CrossRefPubMedGoogle Scholar
  20. Kazantsev AG (2007) Cellular pathways leading to neuronal dysfunction and degeneration. Drug News Perspect 20:501–509CrossRefPubMedGoogle Scholar
  21. Kermani P, Hempstead B (2007) Brain-derived neurotrophic factor: a newly described mediator of angiogenesis. Trends Cardiovasc Med 17:140–143CrossRefPubMedGoogle Scholar
  22. Kim H, Li Q, Hempstead BL, Madri JA (2004) Paracrine and autocrine functions of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in brain-derived endothelial cells. J Biol Chem 279:33538–33546CrossRefPubMedGoogle Scholar
  23. Koto T, Takubo K, Ishida S, Shinoda H, Inoue M, Tsubota K et al (2007) Hypoxia disrupts the barrier function of neural blood vessels through changes in the expression of claudin-5 in endothelial cells. Am J Pathol 170:1389–1397CrossRefPubMedGoogle Scholar
  24. Lazarovici P, Marcinkiewicz C, Lelkes PI (2006) Cross talk between the cardiovascular and nervous systems: neurotrophic effects of vascular endothelial growth factor (VEGF) and angiogenic effects of nerve growth factor (NGF)-implications in drug development. Curr Pharm Des 12:2609–2622CrossRefPubMedGoogle Scholar
  25. Lee JH, Lee J, Seo GH, Kim CH, Ahn YS (2007) Heparin inhibits NF-kappaB activation and increases cell death in cerebral endothelial cells after oxygen–glucose deprivation. J Mol Neurosci 32:145–154CrossRefPubMedGoogle Scholar
  26. Li X, Zhou T, Zhi X, Zhao F, Yin L, Zhou P (2006) Effect of hypoxia/reoxygenation on CD73 (ecto-5'-nucleotidase) in mouse microvessel endothelial cell lines. Microvasc Res 72:48–53CrossRefPubMedGoogle Scholar
  27. Lo EH (2008) Experimental models, neurovascular mechanisms and translational issues in stroke research. Br J Pharmacol 153(Suppl 1):S396–S405CrossRefPubMedGoogle Scholar
  28. Montesano R, Pepper MS, Mohle-Steinlein U, Risau W, Wagner EF, Orci L (1990) Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell 62:435–445CrossRefPubMedGoogle Scholar
  29. Moser KV, Reindl M, Blasig I, Humpel C (2004) Brain capillary endothelial cells proliferate in response to NGF, express NGF receptors and secrete NGF after inflammation. Brain Res 1017:53–60CrossRefPubMedGoogle Scholar
  30. Narasimhan P, Liu J, Song YS, Massengale JL, Chan PH (2009) VEGF Stimulates the ERK 1/2 signaling pathway and apoptosis in cerebral endothelial cells after ischemic conditions. Stroke 40:1467–1473CrossRefPubMedGoogle Scholar
  31. Rahbek UL, Dissing S, Thomassen C, Hansen AJ, Tritsaris K (2005) Nerve growth factor activates aorta endothelial cells causing PI3K/Akt- and ERK-dependent migration. Pflugers Arch 450:355–361CrossRefPubMedGoogle Scholar
  32. Salis MB, Graiani G, Desortes E, Caldwell RB, Madeddu P, Emanueli C (2004) Nerve growth factor supplementation reverses the impairment, induced by type 1 diabetes, of hindlimb post-ischaemic recovery in mice. Diabetologia 47:1055–1063CrossRefPubMedGoogle Scholar
  33. Slevin M, Krupinski J, Slowik A, Rubio F, Szczudlik A, Gaffney J (2000) Activation of MAP kinase (ERK-1/ERK-2), tyrosine kinase and VEGF in the human brain following acute ischaemic stroke. NeuroReport 11:2759–2764CrossRefPubMedGoogle Scholar
  34. Sofroniew MV, Howe CL, Mobley WC (2001) Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci 24:1217–1281CrossRefPubMedGoogle Scholar
  35. Tabakman R, Lazarovici P, Kohen R (2002) Neuroprotective effects of carnosine and homocarnosine on pheochromocytoma PC12 cells exposed to ischemia. J Neurosci Res 68:463–469CrossRefPubMedGoogle Scholar
  36. Tabakman R, Jiang H, Schaefer E, Levine RA, Lazarovici P (2004) Nerve growth factor pretreatment attenuates oxygen and glucose deprivation-induced c-Jun amino-terminal kinase 1 and stress-activated kinases p38alpha and p38beta activation and confers neuroprotection in the pheochromocytoma PC12 model. J Mol Neurosci 22:237–250CrossRefPubMedGoogle Scholar
  37. Tabakman R, Jiang H, Shahar I, Arien-Zakay H, Levine RA, Lazarovici P (2005) Neuroprotection by NGF in the PC12 in vitro OGD model: involvement of mitogen-activated protein kinases and gene expression. Ann N Y Acad Sci 1053:84–96CrossRefPubMedGoogle Scholar
  38. Wang X, Zhou Y, Kim HP, Song R, Zarnegar R, Ryter SW et al (2004) Hepatocyte growth factor protects against hypoxia/reoxygenation-induced apoptosis in endothelial cells. J Biol Chem 279:5237–5243CrossRefPubMedGoogle Scholar
  39. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME (1995) Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270:1326–1331CrossRefPubMedGoogle Scholar
  40. Yamakawa M, Liu LX, Date T, Belanger AJ, Vincent KA, Akita GY et al (2003) Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors. Circ Res 93:664–673CrossRefPubMedGoogle Scholar
  41. Yang W, de Bono DP (1997) A new role for vascular endothelial growth factor and fibroblast growth factors: increasing endothelial resistance to oxidative stress. FEBS Lett 403:139–142CrossRefPubMedGoogle Scholar
  42. Yang MZ, Mun CH, Choi YJ, Baik JH, Park KA, Lee WT et al (2007) Agmatine inhibits matrix metalloproteinase-9 via endothelial nitric oxide synthase in cerebral endothelial cells. Neurol Res 29:749–754CrossRefPubMedGoogle Scholar
  43. Zacchigna S, Lambrechts D, Carmeliet P (2008) Neurovascular signalling defects in neurodegeneration. Nat Rev Neurosci 9:169–181CrossRefPubMedGoogle Scholar
  44. Zhu Y, Sun Y, Xie L, Jin K, Sheibani N, Greenberg DA (2003) Hypoxic induction of endoglin via mitogen-activated protein kinases in mouse brain microvascular endothelial cells. Stroke 34:2483–2488CrossRefPubMedGoogle Scholar
  45. Zhuang S, Schnellmann RG (2006) A death-promoting role for extracellular signal-regulated kinase. J Pharmacol Exp Ther 319:991–997CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Shimon Lecht
    • 1
  • Hadar Arien-Zakay
    • 1
  • Cezary Marcinkiewicz
    • 2
  • Peter I. Lelkes
    • 3
  • Philip Lazarovici
    • 1
    Email author
  1. 1.Department of Pharmacology and Experimental Therapeutics, School of Pharmacy, Faculty of MedicineThe Hebrew University of JerusalemJerusalemIsrael
  2. 2.Department of BiologyTemple UniversityPhiladelphiaUSA
  3. 3.Laboratory of Cellular Tissue Engineering, School of Biomedical Engineering, Science and Health SystemsDrexel UniversityPhiladelphiaUSA

Personalised recommendations